Seroconversion After Coronavirus Disease 2019 Vaccination in Patients Awaiting Liver Transplantation: Fact or Fancy?

Alberto Calleri, Margherita Saracco, Fabrizia Pittaluga, Rossana Cavallo, Renato Romagnoli, Silvia Martini – 25 September 2021 – Chronic liver disease increased the risk of severe coronavirus disease 2019 (COVID‐19). Trials to assess efficacy/safety of COVID‐19 vaccines in liver disease are underway. We evaluated the humoral immune response and safety of anti–COVID‐19 vaccination among patients waiting liver transplantation (LT). We enrolled all pre‐LT adults who completed anti‐COVID‐19 vaccination between January 2021‐August 2021 as study group.

Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis

Peter J. Altshuler, Hien Dang, Adam M. Frank, Ashesh P. Shah, Jaime Glorioso, Tingting Zhan, Arturo Rios Diaz, Osama Shaheen, Carlo B. Ramirez, Warren R. Maley, Adam S. Bodzin – 25 September 2021 – The increasing prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects both recipient and donor populations in liver transplantation. Presently, it is unclear whether transplantation of macrosteatotic allografts is affected by the metabolic milieu of liver transplant recipients.

The Prediction of In‐Hospital Mortality in Decompensated Cirrhosis with Acute‐on‐Chronic Liver Failure

Florence Wong, K. Rajender Reddy, Puneeta Tandon, Jennifer C. Lai, Nishita Jagarlamudi, Vanessa Weir, Beverley Kok, Sylvia Kalainy, Yanin T. Srisengfa, Somaya Albhaisi, Bradley Reuter, Chathur Acharya, Jawaid Shaw, Leroy R. Thacker, Jasmohan S. Bajaj – 25 September 2021 – Acute‐on‐chronic liver failure (ACLF) is a condition in cirrhosis associated with organ failure (OF) and high short‐term mortality.

Hepatology Highlights

Chaitanya Allamneni, Ravi S. Vora, Adebowale O. Bamidele, Robert E. Schwartz, Davide Povero, David M. Salerno, Robert S. Brown, Rosa Lu Yu, Mati Ullah Dad Ullah, Daryl T.Y. Lau, Wei Zhang, Amani Lee, Enis Kostallari, Nidhi Jalan‐Sakrikar, Shalil Khanal, Enis Kostallari – 23 September 2021

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

Lisa Sandmann, Cihan Yurdaydin, Katja Deterding, Benjamin Heidrich, Svenja Hardtke, Patrick Lehmann, Birgit Bremer, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Benjamin Maasoumy, HIDIT‐II Study Group – 23 September 2021 – Standard treatment of hepatitis delta virus (HDV) infection remains pegylated‐interferon alfa (peg‐IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events.

Offer Acceptance Patterns for Liver Donors Aged 70 and Older

Christine E. Haugen, Mary G. Bowring, Kyle R. Jackson, Jacqueline Garonzik‐Wang, Allan B. Massie, Teresa Po‐Yu Chiang, Benjamin Philosophe, Dorry L. Segev, Karim J. Halazun – 23 September 2021 – Despite a documented survival benefit, older liver donor (OLD, age ≥70) graft offers are frequently declined, with utilization worsening over the last decade. To understand how offer acceptance varies by center, we studied 1113 eventually transplanted OLD grafts from 2009 to 2017 using Scientific Registry of Transplant Recipients (SRTR) data and random‐intercept multilevel logistic regression.

Subscribe to